secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001437749-23-008527
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics appoints Wendy L. Dixon, Ph.D. to board of directors
-----------------------------------------------------------------------

- Dr. Dixon appointed effective after April 25, 2023 annual meeting, filling vacancy from Dr. Travis Mickle's resignation.
- She will serve as Class I director with term expiring at 2025 annual meeting.
- Initial option grant of 22,500 shares vesting over three years; annual retainer of $40,000.
- Dr. Dixon has over 40 years biopharma experience, previously CMO at Bristol Myers Squibb and SVP at Merck.
- No family relationships or reportable transactions under Item 404(a) of Regulation S-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/0001437749-23-008527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923008527/zvra20230328_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer